Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy

American Journal of Transplantation

Volumn 10, Issue 12, 2010, Pages 2615-2623

  Schaub, S ^a   Hirsch, H H ^a,b   Dickenmann, M ^a   Steiger, J ^a   Mihatsch, M J ^b   Hopfer, H ^b   Mayr, M ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Allograft rejection; polyoma BK virus; polyomavirus associated nephropathy; reduction of immunosuppression; surveillance biopsies

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CREATININE; CYCLOSPORIN A; HLA DR ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; BK VIRUS; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY CELL; KIDNEY DECOY CELL; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; PLASMA CLEARANCE; POLYOMAVIRUS ASSOCIATED NEPHROPATHY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCTION OF IMMUNOSUPPRESSION; SCHOOL CHILD; SINGLE DRUG DOSE; STEROID THERAPY; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; BK VIRUS; CREATININE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VIREMIA;

EID: 78649810345     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03310.x     Document Type: Article

References (39)

1. Ramos E, Drachenberg CB, Wali R, Hirsch HH,. The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation 2009; 87: 621-630.
2. Weiss AS, Gralla J, Chan L, Klem P, Wiseman AC,. Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: A comparison of two reduction strategies. Clin J Am Soc Nephrol 2008; 3: 1812-1819.
3. Wadei HM, Rule AD, Lewin M, et al,. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 2006; 6: 1025-1032.
4. Nickeleit V, Klimkait T, Binet IF, et al,. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309-1315.
5. Hirsch HH, Knowles W, Dickenmann M, et al,. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488-496.
6. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC,. BK-Virus and the Impact of Pre-Emptive Immunosuppression Reduction: 5-Year Results. Am J Transplant 2010; 10: 407-415.
7. Ginevri F, Azzi A, Hirsch HH, et al,. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727-2735.
8. Almeras C, Foulongne V, Garrigue V, et al,. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 2008; 85: 1099-1104.
9. Saad ER, Bresnahan BA, Cohen EP, et al,. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85: 850-854.
10. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP,. BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834-1839.
11. Viscount HB, Eid AJ, Espy MJ, et al,. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 2007; 84: 340-345.
12. Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S,. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626-632.
13. Bachler K, Amico P, Honger G, et al,. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254-1262.
14. Oettl T, Halter J, Bachmann A, et al,. ABO blood group-incompatible living donor kidney transplantation: A prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant 2009; 24: 298-303.
15. Hirsch HH, Mohaupt M, Klimkait T,. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 2001; 184: 1494-1495.
16. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
17. Hirsch HH, Brennan DC, Drachenberg CB, et al,. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277-1286.
18. Hirsch HH, Randhawa P,. BK virus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S136-S146.
19. Brennan DC, Agha I, Bohl DL, et al,. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582-594.
20. Ramos E, Drachenberg CB, Papadimitriou JC, et al,. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145-2151.
21. Manitpisitkul W, Drachenberg C, Ramos E, et al,. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: A case-control study. Transplantation 2009; 88: 83-88.
22. Prince O, Savic S, Dickenmann M, Steiger J, Bubendorf L, Mihatsch MJ,. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009; 24: 1024-1033.
23. Dadhania D, Snopkowski C, Ding R, et al,. Epidemiology of BK virus in renal allograft recipients: Independent risk factors for BK virus replication. Transplantation 2008; 86: 521-528.
24. Awadalla Y, Randhawa P, Ruppert K, Zeevi A, Duquesnoy RJ,. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004; 4: 1691-1696.
25. Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU,. Treatment for BK virus: Incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22: 626-634.
26. Dharnidharka VR, Cherikh WS, Abbott KC,. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019-1026.
27. Randhawa P, Farasati NA, Shapiro R, Hostetler KY,. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother 2006; 50: 1564-1566.
28. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH,. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008; 8: 1413-1422.
29. Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH,. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol 2010; 84: 2150-2156.
30. Funk GA, Hirsch HH,. From plasma BK viral load to allograft damage: Rule of thumb for estimating the intrarenal cytopathic wear. Clin Infect Dis 2009; 49: 989-990.
31. Egli A, Kohli S, Dickenmann M, Hirsch HH,. Inhibition of polyomavirus BK-specific T Cell responses by immunosuppressive drugs. Transplantation 2009; 88: 1161-1168.
32. Mannon RB, Hoffmann SC, Kampen RL, et al,. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 2005; 5: 2883-2893.
33. Schaub S, Mayr M, Egli A, et al,. Transient allograft dysfunction from immune reconstitution in a patient with polyoma BK-virus-associated nephropathy. Nephrol Dial Transplant 2007; 22: 2386-2390.
34. Nickeleit V, Hirsch HH, Zeiler M, et al,. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15: 324-332.
35. Celik B, Shapiro R, Vats A, Randhawa PS,. Polyomavirus allograft nephropathy: Sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant 2003; 3: 1378-1382.
36. Kayler LK, Batal I, Mohanka R, et al,. Antirejection treatment in kidney transplant patients with BK viruria. Transplantation 2008; 86: 797-803.
37. Batal I, Franco ZM, Shapiro R, et al,. Clinicopathologic analysis of patients with BK viruria and rejection-like graft dysfunction. Hum Pathol 2009; 40: 1312-1319.
38. Binggeli S, Egli A, Schaub S, et al,. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007; 7: 1131-1139.
39. Helantera I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH,. Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24: 339-371.